Abstract:Given the long follow-up periods that are often required for treatment or intervention studies, the potential to use surrogate markers to decrease the required follow-up time is a very attractive goal. However, previous studies have shown that using inadequate markers or making inappropriate assumptions about the relationship between the primary outcome and surrogate marker can lead to inaccurate conclusions regarding the treatment effect. Currently available methods for identifying and validating surrogate markers tend to rely on restrictive model assumptions and/or focus on uncensored outcomes. The ability to use such methods in practice when the primary outcome of interest is a time-to-event outcome is difficult due to censoring and missing surrogate information among those who experience the primary outcome before surrogate marker measurement. In this paper, we propose a novel definition of the proportion of treatment effect explained by surrogate information collected up to a specified time in the setting of a time-to-event primary outcome. Our proposed approach accommodates a setting where individuals may experience the primary outcome before the surrogate marker is measured. We propose a robust nonparametric procedure to estimate the defined quantity using censored data and use a perturbation-resampling procedure for variance estimation. Simulation studies demonstrate that the proposed procedures perform well in finite samples. We illustrate the proposed procedures by investigating two potential surrogate markers for diabetes using data from the Diabetes Prevention Program.

CRITERIA FOR MULTIPLE SURROGATES

Criteria for surrogate end points

Novel Criteria to Exclude the Surrogate Paradox and Their Optimalities

Criteria for surrogate end points based on causal distributions

Sufficient conditions for concluding surrogacy based on observed data.

Estimating Treatment Effects using Multiple Surrogates: The Role of the Surrogate Score and the Surrogate Index

On the individual surrogate paradox

Surrogacy Beyond Prognosis: The Importance of “Trial-Level” Surrogacy

Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm

Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity

Evaluating Surrogate Marker Information using Censored Data

On the Evaluation of Surrogate Markers in Real World Data Settings

Response‐Adaptive Randomization Procedure in Clinical Trials with Surrogate Endpoints

A new proportion measure of the treatment effect captured by candidate surrogate endpoints

Surrogate endpoint meta-regression: Useful statistics for regulators and trialists

Continuous Treatment Effects with Surrogate Outcomes

Evaluating time-to-event surrogates for time-to-event true endpoints: an information-theoretic approach based on causal inference

On the role of surrogates in the efficient estimation of treatment effects with limited outcome data

Establishing and Using Threshold of Surrogate Endpoint in Relation to Clinical Endpoint

Using a Surrogate with Heterogeneous Utility to Test for a Treatment Effect

Principal causal effect identification and surrogate endpoint evaluation by multiple trials